BCAB

BioAtla Inc. (BCAB) | Rumor.io

BioAtla

BCAB

Attention (50-day avg)0%

Attention rank (50-day avg)#2,465

Bullish sentiment (50-day avg)58%

Price to earnings ratio-0.03

Market capitalization2.7M

Earnings per share-25.1

Dividend yield (TTM)—

Revenue (annual)2M

Net income (annual)-59.6M

Social

What share of all stock conversation is about BCAB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

Aug 28

BioAtla, Inc. ($BCAB) will be delisted from the Nasdaq on August 31, 2026, due to non-compliance with listing requirements, specifically the $1.00 minimum bid-price rule and the $2.5 million minimum stockholders' equity requirement.
The delisting decision was affirmed by the Nasdaq Listing Council on August 26, 2026, and trading on the Nasdaq will be suspended on August 31, with the company expected to transition to OTC Markets.
BioAtla's shares have traded at a significantly lower price, down 47.1% to $1.66, with a total of 212K shares traded on the day, following the delisting news and the suspension of trading on the Nasdaq.

Generated by AI

Sentiment

Of the messages about BCAB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	50% -10	72.47% -9.77
Bearish	0%	0%	50% +10	27.53% +9.77

Bullish· Dec 31

The company has secured a $40M deal for 35% of its asset Oz-V, providing significant funding for the pivotal Phase 3 trial.
The deal is considered non-dilutive, with the company retaining 65% ownership of Oz-V and full rights to its pipeline, including EpCAM and AXLT.
The valuation of Oz-V alone is estimated to be around $114M, significantly higher than the current market cap of the company, indicating potential for substantial upside.

Bearish· Apr 7

The company's market cap is likely less than a private individual's house, indicating a significant undervaluation.
The stock is at risk of being delisted from the NASDAQ, which could lead to a further decline in value.
The company is facing a high likelihood of bankruptcy, with some predicting a 60% drop in value within a short timeframe.

Generated by AI

Topics

Of the messages about BCAB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	72.55%
Analysts	—	—	0%	2.25%
Controversies	—	—	0%	0%
Earnings	—	—	0%	1.35%
Macro	—	—	0%	0.11%
Technical Analysis	—	—	0%	23.73%

Dec 31

BioAtla, Inc. (BCAB) announces a $40M Special Purpose Vehicle (SPV) transaction with GATC Health to advance Ozuriftamab Vedotin (Oz-V) into a registrational trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC).
The deal includes $5M in initial cash for operations and Phase 3 costs, with the remaining $35M committed pending Q1 2026 close, and BioAtla retains 65% ownership of Oz-V across solid tumors.
BioAtla expects to use the gross proceeds to fund clinical trial expenses and advance Oz-V in a Phase 3 Study in 2L+ oropharyngeal squamous cell carcinoma.

Generated by AI

Community

Of the messages about BCAB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	31.43%	73.09%
Newcomers	0%	0%	68.57%	26.91%

Regulars· Aug 28

BioAtla, Inc. (BCAB) has been warned by Nasdaq that its listing will be suspended on August 31, with shares likely moving to OTC markets, due to non-compliance with listing requirements.
The company's decision to monetize its Oz-V asset was criticized for being too slow, with some questioning the leadership's ability to manage the company's finances and leverage.
BioAtla's delisting from Nasdaq has been confirmed, and the company is expected to transition to OTC Markets, which may have an adverse effect on its stock price and future clinical trials.

Newcomers· Aug 28

BioAtla, Inc. ($BCAB) has been delisted by Nasdaq due to non-compliance with the $1.00 minimum bid-price rule and the $2.5 million minimum stockholders' equity requirement.
The delisting is expected to be effective on August 31, 2026, and trading on Nasdaq will be suspended at that time.
The company's cash reserves are limited to $1.54 million, and it has an accumulated deficit of $551.5 million, with no buyer identified and a "strategic review" announced since March.

Generated by AI

News

BioAtla Shareholders Back Directors, Auditor and Pay Plan

Detailed price information for Bioatla Inc (BCAB-Q) from The Globe and Mail including charting and trades.

2mo agoThe Globe and Mail

Also Discussed

Investors talking about BCAB also mention

#	Name	Attention
1	Rallybio Corp.RLYB	0%0
2	Prelude Therapeutics IncorporatedPRLD	0%0
3	ImageneBio, Inc.IKNA	0%0
4	RVPH - Reviva Pharmaceuticals Holdings, Inc.	——
5	Sutro Biopharma Inc.STRO	0%new
6	CytomX Therapeutics, Inc.CTMX	0%0
7	Olaplex Holdings, Inc.OLPX	0%0
8	MRSN - Mersana Therapeutics, Inc.	——
9	RPTX - Repare Therapeutics Inc.	——
10	Xilio Therapeutics, Inc.XLO	0%0

BioAtla Inc.

Healthcare
Biotechnology

BioAtla Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for solid tumor cancers. BioAtla Inc. applies its proprietary conditionally active biologic platform to create monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates designed to become active in the tumor microenvironment while limiting activity in healthy tissues. Its current portfolio includes product candidates aimed at difficult-to-treat cancers such as non-small cell lung cancer, sarcoma, melanoma, and head and neck squamous cell carcinoma. The company’s work centers on advancing targeted oncology programs that are intended to improve selectivity and therapeutic precision in cancer treatment. Headquartered in San Diego, California, BioAtla Inc. operates as part of the biotechnology sector and remains focused on research, development, and clinical evaluation of its antibody therapeutics.

Website

Location

11085 Torreyana Road

San Diego, CA, 92121

United States

Social

What share of all stock conversation is about BCAB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

Aug 28

BioAtla, Inc. ($BCAB) will be delisted from the Nasdaq on August 31, 2026, due to non-compliance with listing requirements, specifically the $1.00 minimum bid-price rule and the $2.5 million minimum stockholders' equity requirement.
The delisting decision was affirmed by the Nasdaq Listing Council on August 26, 2026, and trading on the Nasdaq will be suspended on August 31, with the company expected to transition to OTC Markets.
BioAtla's shares have traded at a significantly lower price, down 47.1% to $1.66, with a total of 212K shares traded on the day, following the delisting news and the suspension of trading on the Nasdaq.

Generated by AI

Sentiment

Of the messages about BCAB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	50% -10	72.47% -9.77
Bearish	0%	0%	50% +10	27.53% +9.77

Bullish· Dec 31

The company has secured a $40M deal for 35% of its asset Oz-V, providing significant funding for the pivotal Phase 3 trial.
The deal is considered non-dilutive, with the company retaining 65% ownership of Oz-V and full rights to its pipeline, including EpCAM and AXLT.
The valuation of Oz-V alone is estimated to be around $114M, significantly higher than the current market cap of the company, indicating potential for substantial upside.

Bearish· Apr 7

The company's market cap is likely less than a private individual's house, indicating a significant undervaluation.
The stock is at risk of being delisted from the NASDAQ, which could lead to a further decline in value.
The company is facing a high likelihood of bankruptcy, with some predicting a 60% drop in value within a short timeframe.

Generated by AI

Topics

Of the messages about BCAB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	72.55%
Analysts	—	—	0%	2.25%
Controversies	—	—	0%	0%
Earnings	—	—	0%	1.35%
Macro	—	—	0%	0.11%
Technical Analysis	—	—	0%	23.73%

Dec 31

BioAtla, Inc. (BCAB) announces a $40M Special Purpose Vehicle (SPV) transaction with GATC Health to advance Ozuriftamab Vedotin (Oz-V) into a registrational trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC).
The deal includes $5M in initial cash for operations and Phase 3 costs, with the remaining $35M committed pending Q1 2026 close, and BioAtla retains 65% ownership of Oz-V across solid tumors.
BioAtla expects to use the gross proceeds to fund clinical trial expenses and advance Oz-V in a Phase 3 Study in 2L+ oropharyngeal squamous cell carcinoma.

Generated by AI

Community

Of the messages about BCAB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	31.43%	73.09%
Newcomers	0%	0%	68.57%	26.91%

Regulars· Aug 28

BioAtla, Inc. (BCAB) has been warned by Nasdaq that its listing will be suspended on August 31, with shares likely moving to OTC markets, due to non-compliance with listing requirements.
The company's decision to monetize its Oz-V asset was criticized for being too slow, with some questioning the leadership's ability to manage the company's finances and leverage.
BioAtla's delisting from Nasdaq has been confirmed, and the company is expected to transition to OTC Markets, which may have an adverse effect on its stock price and future clinical trials.

Newcomers· Aug 28

BioAtla, Inc. ($BCAB) has been delisted by Nasdaq due to non-compliance with the $1.00 minimum bid-price rule and the $2.5 million minimum stockholders' equity requirement.
The delisting is expected to be effective on August 31, 2026, and trading on Nasdaq will be suspended at that time.
The company's cash reserves are limited to $1.54 million, and it has an accumulated deficit of $551.5 million, with no buyer identified and a "strategic review" announced since March.

Generated by AI

BioAtla

Social

Aug 28

Bullish· Dec 31

Bearish· Apr 7

Dec 31

Regulars· Aug 28

Newcomers· Aug 28

BioAtla Shareholders Back Directors, Auditor and Pay Plan

Also Discussed

BioAtla Inc.

Company Information

Location

BioAtla Shareholders Back Directors, Auditor and Pay Plan

Also Discussed

Social

Aug 28

Bullish· Dec 31

Bearish· Apr 7

Dec 31

Regulars· Aug 28

Newcomers· Aug 28